Marinus Pharmaceuticals, Inc (MRNS)

Etorro trading 970x250
Marinus Pharmaceuticals, Inc (MRNS) Logo

About Marinus Pharmaceuticals, Inc

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. Address: 5 Radnor Corporate Center, Radnor, PA, United States, 19087

Marinus Pharmaceuticals, Inc News and around…

Latest news about Marinus Pharmaceuticals, Inc (MRNS) common stock and company :

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
18 May, 2022 FinancialContent

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Recap: Marinus Pharma Q1 Earnings
12 May, 2022 FinancialContent

Marinus Pharma (NASDAQ:MRNS) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know ...

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
12 May, 2022 Yahoo! Finance

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
12 May, 2022 FinancialContent

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BridgeBio Inks Licensing ...

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10 May, 2022 FinancialContent

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
05 May, 2022 Yahoo! Finance

Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out for
05 May, 2022 Yahoo! Finance

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12 Health Care Stocks Moving In Thursday's Pre-Market Session
05 May, 2022 FinancialContent

Gainers Intercept Pharmaceuticals (NASDAQ:ICPT) stock increased by 41.2% to $22.86 during Thursday's pre-market ...

Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
05 May, 2022 FinancialContent

Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

3 Biotech Stocks Under $10 to Add to Your Buy List
26 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
20 Apr, 2022 FinancialContent

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022

Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
14 Apr, 2022 FinancialContent

Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
01 Apr, 2022 FinancialContent

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is ...

Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
31 Mar, 2022 FinancialContent

Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
27 Mar, 2022 Yahoo! Finance

Celebrations may be in order for Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) shareholders, with the analysts...

Analyzing Marinus Pharmaceuticals Inc's Short Interest
22 Mar, 2022 FinancialContent

Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) short percent of float has risen 9.74% since its last report. The company recently reported ...

Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder
21 Mar, 2022 Yahoo! Finance

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

12 Health Care Stocks Moving In Monday's Pre-Market Session
21 Mar, 2022 FinancialContent

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value ...

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
21 Mar, 2022 Yahoo! Finance

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Marinus Pharmaceuticals Q4 Earnings
21 Mar, 2022 FinancialContent

Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q4 earnings results on Monday, March 21, 2022 at 07:15 AM. Here's ...

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
21 Mar, 2022 FinancialContent

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Earnings Scheduled For March 21, 2022
21 Mar, 2022 FinancialContent

Companies Reporting Before The Bell • Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at ...

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
20 Mar, 2022 FinancialContent

Biotech stocks rebounded along with the broader market in the week endingMarch 18, as risk appetite returned. Multiple conference ...

Here's Why Marinus Pharmaceuticals Shares Are Moving
18 Mar, 2022 FinancialContent

Marinus Pharmaceuticals Inc (NASDAQ: MRNS)shares are trading higher by 25.0% at $10.72 after the company announced the FDA has ...

UPDATE 2-U.S. FDA approves Marinus Pharma's drug to treat seizures; shares jump
18 Mar, 2022 Yahoo! Finance

The U.S. health regulator has approved Marinus Pharmaceuticals Inc's lead drug to treat seizures associated with a rare genetic disorder in patients two years of age and older, the company said on Friday, sending its shares soaring around 36%. The oral drug, which will be sold under the brand name Ztalmy, is for treatment of seizures associated with CDKL5 deficiency disorder, a rare genetic epilepsy. Ztalmy is expected to be commercially available in the United States in July following scheduling by the U.S. Drug Enforcement Administration, Marinus said in a statement.

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
18 Mar, 2022 FinancialContent

Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder

Preview: Marinus Pharmaceuticals's Earnings
18 Mar, 2022 FinancialContent

Marinus Pharmaceuticals (NASDAQ:MRNS) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors ...

Notable Thursday Option Activity: AVAV, MRNS, COST
17 Mar, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AeroVironment, Inc. (AVAV), where a total of 5,511 contracts have traded so far, representing approximately 551,100 underlying shares..

TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates
10 Mar, 2022 Yahoo! Finance

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals, Inc (MRNS) is a NASDAQ Common Stock listed in , ,

970x250